Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen’s next CSO walks into roxadustat rebuff

Neil Berkley

→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the monoclonal antibody in March, followed by a similar halt for the combo treatment with etesevimab late last month....

Click to view original post